The economic impact of cytomegalovirus infection after liver transplantation

Transplantation

Volumn 69, Issue 3, 2000, Pages 357-361

  Kim, W Ray ^a   Badley, Andrew D ^a,b   Wiesner, Russell H ^a   Porayko, Michael K ^a   Seaberg, Eric C ^a   Keating, Michael R ^a   Evans, Roger W ^a   Dickson, E Rolland ^a   Krom, Ruud A F ^c   Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITAL BILLING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

EID: 0034001174     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002150-00008     Document Type: Article

References (23)

1. Patel R, Paya CV. Infection in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10: 86.
2. Wiesner RH, Marin E, Porayko MK, Steers JL, Krom RAF, Paya CV. Advanced in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. Gastroenterol Clin N Am 1993; 22: 351.
3. Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988; 10: S460.
4. Paya CV, Wiesner RH, Herman PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
5. Paya CV. Opportunistic infections: risk factor or virus-associated complication? Transplant Proc 1994; 12.
6. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
7. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of GCV and high-dose ACV for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995; 346: 69.
8. Gane E, Saliba F, Valdecasas GJC, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729.
9. Badley AD, Seaberg EC, Porayko MK, et al. Prophylaxis of cytomegalovirus infection in liver transplantation. Transplantation 1997; 64: 66.
10. Patel R, Smith TF, Espy M, et al. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis 1995; 171: 1010.
11. Kim WR, Therneau TM, Dickson ER, et al. Preoperative predictors of resource utilization in liver transplantation. In: Terasaki PI, Cecka MM, eds. Clinical transplants. UCLA tissue typing laboratory. Los Angeles, CA. 1995; 315.
12. Drummond M, Stoddart G, Labelle R, Cushman R. Health economics: an introduction for clinicians. Ann Intern Med 1987; 107: 88.
13. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term "cost effective" in medicine. N Engl J Med 1986; 314: 253.
14. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997; 126: 275.
15. Bronsther O, Makowka L, Jaffe R, et al. Occurrence of cytomegalovirus hepatitis in liver transplant patients. J Med Virol 1988; 24: 423.
16. Falagas ME, Arbo M, Ruthazer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997; 63: 1595.
17. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103: 106.
18. O'Grady JG, Alexander GJ, Sutherland S, Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988; 2: 302.
19. Patel R. Portela DF, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections following liver transplantation. Transplantation 1996; 62: 926.
20. Badley AD, Patel R, Portela DF, et al. Prognostic significance and risk factors of untreated CMV viremia in liver transplant recipients. J Infect Dis 1996; 173: 446.
21. Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for CMV disease in liver transplantation. J Infect Dis 1995; 171: 1014.
22. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High dose ACV compared with short-course preemptive GCV therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994; 120: 375.
23. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. London: Oxford Medical Publications, 1997.